--- a
+++ b/clusters/9knumclustersv2/clust_1183.txt
@@ -0,0 +1,72 @@
+Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least  week prior to enrollment
+Stable dose of corticosteroids for at least  days
+If patients are on corticosteroids, they must have been on a stable or decreasing dose >=  days prior to obtaining their baseline gadolinium (Gd)-magnetic resonance imaging (MRI) of brain; this MRI is to be obtained within  days of registration; NOTE: If patient needs escalation of steroids prior to therapy, or are on unstable doses of steroids they are not eligible
+For subjects on corticosteroids for endocrine deficiencies or tumor-associated symptoms, must be on a stable (or decreasing) dose for at least  days before first dose of study treatment.
+Patients who are on dexamethasone must be on a stable or decreasing dose for at least one week prior to registration
+Participants must have bi-dimensionally measurable disease with a minimum measurement of  cm per dimension on MRI performed within  days prior to registration; if receiving corticosteroids, participants must be on a stable or decreasing dose of corticosteroids for at least  days prior to baseline MRI
+Steroid regimen stable or decreasing for at least  days prior to inoculation
+Corticosteroids: patients who are receiving dexamethasone must be on a stable or decreasing dose for at least  week prior to registration
+Stable or decreasing steroid dose within  weeks of first dose of study drug if patient is taking steroids. No steroid use is also acceptable.
+For patients with HGG and receiving glucocorticoid therapy, must be on stable or decreasing equivalent daily dose of glucocorticoids for  weeks ( days) prior to dose assignment
+Patients receiving unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms other than CNS related, dose must have been stabilized (or decreasing) for at least  days before first dose of INC
+Corticosteroids: patients who are receiving dexamethasone or other corticosteroids must be on a stable or decreasing dose for at least  week prior to enrollment; it is recommended that patients be off all steroid therapy or receive the least dose that will control their neurologic symptoms
+Patients enrolling in the medical arm (Arms C and D) must be on a stable or decreasing dose of corticosteroids (or none) for at least  days prior to the baseline MRI;
+If on corticosteroids for mass effect and/or edema related to the tumor, patient must be on a stable or decreasing dose for at least  weeks prior to study entry
+Corticosteroids: Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least  week prior to registration.
+STRATUM A: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least  week prior to study enrollment with no plans for escalation
+STRATUM B: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least  week prior to study enrollment with no plans for escalation
+STRATUM C: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least  week prior to study enrollment with no plans for escalation
+Corticosteroids: patients who are receiving dexamethasone must be on a stable or decreasing dose for at least  week prior to registration
+Patients requiring steroids must be at a stable or decreasing dose for at least  week prior to enrollment
+Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least  week prior to registration
+Stable or decreasing steroid dose (=<  mg/day) at time of post-external beam radiation therapy (XRT) adjuvant TMZ initiation; if patients are decreasing steroid use, once they are at  mg/day, they may be supplemented with hydrocortisone, at the discretion of the treating oncologist
+Patients must be on a stable or decreasing dose of corticosteroids within  days prior to CT scan or MRI (which is done to determine eligibility); patients must be on no more than  mg a day but an attempt should be made to keep the dose at  mg or less; please contact the PI if doses of >  mg are needed
+If receiving corticosteroids, patients must be on a stable or decreasing dose of corticosteroids for ?  days prior to baseline MRI.
+Stable and/or decreasing dose of corticosteroids for greater than or equal to  days.
+CAPMATINIB EXCLUSION CRITERIA: Patients on unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms other than CNS related, dose must have been stabilized or decreasing for at least  days before first dose of capmatinib
+Subjects who are receiving corticosteroids must be on a stable or decreasing dose for at least  weeks before first dose of study treatment.
+Steroids: patients who are receiving corticosteroids must be on a stable or decreasing dose for at least  week prior enrollment in the study
+Fixed or decreasing dose of corticosteroids (or no corticosteroids) for at least  week prior to cycle  day 
+If patient is on corticosteroids, the dose must be stable or decreasing for at least  days prior to enrollment
+Have brain metastases that are neurologically unstable or require an increasing dose of corticosteroids. Patients must be on a stable or decreasing dose of corticosteroids for  days prior to first dose of AP.
+If receiving concomitant corticosteroids, must be on a stable or decreasing dose for at least  days prior to the baseline Gd-MRI.
+Patients who are receiving corticosteroids must be on a stable or decreasing dose for at least  week prior to registration
+Corticosteroids: Participants receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to study drug administration (except when indicated for Central Nervous System [CNS] metastases, then participants must not have received corticosteroids for at least  days)
+If patient is receiving steroids, must be on stable or decreasing steroid dose within  days prior to treatment initiation with SGT-.
+Stable or decreasing dose of steroids for at least  days at the time of baseline brain MRI.
+Fixed or decreasing dose of corticosteroids (or no corticosteroids) >=  days prior to registration
+Baseline MRI within  days of Day  & on steroid dosage that has been stable or decreasing for at least  days
+Patients who were receiving corticosteroids have to receive a stable or decreasing dose for at least  days before study entry
+If corticosteroids are required for controlling cerebral edema, patients must be on a stable dose of at least  week prior to enrollment
+Documentation of steroid doses - days prior to study registration and stable or decreasing steroid dose over the week prior to registration
+Stable or decreasing dose of corticosteroids within  days prior to study . enrollment.
+Concurrent use of iron-chelating agents, (except for subjects on a stable or decreasing dose for at least  weeks ( days) prior to randomization), corticosteroid (except for subjects on a stable or decreasing dose for ?  week prior to randomization for medical conditions other than MDS)
+If receiving corticosteroids, patients must be on a stable or decreasing dose of corticosteroids for ?  days prior to baseline MRI.
+Stable or decreasing dose of corticosteroids prior to treatment with a goal of  mg or less of dexamethasone
+Patients must be on a stable or decreasing dose of corticosteroids for a minimum of  days before the baseline MRI/CT; if the corticosteroid dose is increased between the date of imaging and the initiation of study treatment, a new baseline MRI/CT is required; definition of stable steroids includes patients on no steroids
+For those patients in which steroids are clinically indicated, there must be a stable or decreasing dose of steroid medication for >= one week prior to the start of infusion
+Fixed or decreasing dose of corticosteroids (or no corticosteroids) >=  days prior to registration
+Patients must have been on a stable dose of corticosteroids >=  days prior to obtaining their baseline gadolinium (Gd)-MRI of brain
+Patients must be on a stable or decreasing dexamethasone dosage for at least  week prior to baseline MRI
+Neurological deficits must be stable on a fixed or decreasing dose of dexamethasone for >=  days before study enrollment
+Steroids: patients who are receiving corticosteroids must be on a stable or decreasing dose for at least  week prior to baseline MRI
+Patients must be on a stable or decreasing dose of steroids for at least two weeks prior to randomization
+Subjects who are receiving concomitant corticosteroids must be on a stable or decreasing dose for at least  weeks prior to first dose of study treatment and off all anticonvulsants for at least  weeks prior to study entry.
+Baseline MRI must be performed after subject signs informed consent form (ICF), within  days of Day , & on steroid dosage that has been stable or decreasing for at least  days
+Patients must have no residual neurologic symptoms while taking no steroids, a stable or decreasing dose of steroids, or a stable dose of anti-seizure medication for the  weeks prior to enrollment.
+Patients who are not on a stable or decreasing steroid dose for the previous week prior to the first dose of study enrollment
+If receiving corticosteroids, patients must have been on a stable or decreasing dose of corticosteroids and no more than  mg dexamethasone (or equivalent) for at least  days prior to date of enrollment.
+Stable or decreasing dose of corticosteroids for at least  days prior to randomization.
+Neurological symptoms related to brain metastasis that are not controlled with a stable or decreasing dose of oral steroids for at least  days prior to starting GSK
+Patients receiving unstable or increasing doses of corticosteroids. If patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms, dose must have been stabilized (or decreasing) for at least  days before first dose of study treatment.
+Fixed or decreasing dose of corticosteroids (or no corticosteroids) >=  days prior to registration
+Patients must be on a steroid dose that has been stable or decreasing for at least  days; if the steroid dose is increased between the date of imaging and registration, a new baseline MRI is required
+if receiving corticosteroids, dose is stable or decreasing for past  days
+Unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms (non-CNS), dose must have been stabilized (or decreasing) for at least  days before first dose of study treatment\r\n* Topical and inhaled steroids are allowed
+Must have been taking a stable dose of corticosteroids for symptom management for at least  week before baseline MRI
+Patients must have adequate seizure control and be on a stable, or decreasing, dose of anti-epileptics
+Stable dose of corticosteroids for  weeks prior to enrollment
+Concurrent use of corticosteroids unless the subject is on a stable or decreasing dose for ?  week prior to enrollment for medical conditions other than MDS (MYELODYSPLASTIC SYNDROMES)
+On a stable or decreasing dose of dexamethasone for the previous  days
+Patients receiving corticosteroids are eligible provided the dose is stable or decreasing for at least  days
+Stable or decreasing dose of corticosteroids over  days prior to first MRZ dose